FIELD: medicine, oncology, pharmacy.
SUBSTANCE: invention relates to drugs, namely, to using homoligand fluoride chelate compounds of antimony (III) with cations of monovalent metals wherein the ratio of fluorine atoms to antimony is in the range from 3.5 to 5.0. Proposed compounds are used as an anti-tumor agent. Invention provides expanding assortment of anti-tumor agents based on finding novel properties in the known compounds.
EFFECT: valuable medicinal properties of preparation.
1 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROCEDURE FOR PRODUCTION OF METALLIC ANTIMONY OUT OF ANTIMONY RAW MATERIAL | 2010 |
|
RU2409686C1 |
| AGENT INHIBITING MULTIPLE DRUG RESISTANCE OF TUMOUR CELLS | 2012 |
|
RU2494742C1 |
| DRUG WITH ANTITUMOR ACTIVITY AND METHOD OF ITS PREPARATION | 2023 |
|
RU2813724C1 |
| AGENT FOR CORRECTING CYTOTOXIC EFFECTS OF PARANEOPLASTIC PROCESSES AND CHEMOTHERAPY SHOWING ANTICANCER ACTIVITY | 2011 |
|
RU2447888C1 |
| METHOD OF PREPARING A CARBOHYDRATE-PROTEIN COMPLEX FROM JAPANESE SCALLOP | 1996 |
|
RU2121844C1 |
| AGENT HAVING ANTI-TUMOUR ACTIVITY | 2023 |
|
RU2819039C1 |
| COMPOSITION FOR KILLING TNF-α-SENSITIVE TUMOR CELLS | 2002 |
|
RU2209078C1 |
| COMPLEX ANTI-TUMORAL PRODUCT | 2020 |
|
RU2751776C2 |
| ARILMETHYLENE BISPIRAN-2-ONE-BASED COMPLEX COMPOUNDS OF COPPER(II) EXHIBITING CYTOTOXIC ACTIVITY TO HELA CELL LINE | 2020 |
|
RU2753853C1 |
| IMMUNOMODULATING AGENT AND PHARMACEUTICAL COMPOSITION BASED ON THE SAME | 2004 |
|
RU2271820C1 |
